Anti-Inflammatory Supplements

01Curcuminhuman trials, mostly short

the guide

the yellow polyphenol of turmeric and the most-trialled supplement on the bench. in a human myeloid cell line it blocked the activation of NF-kB, a transcription factor that the inflammatory signal TNF switches on (Singh 1995). swallowed, it is poorly absorbed: in 24 healthy volunteers, each given one dose at levels that rose step by step, curcumin turned up in serum in only two people, both at the top two levels (Lao 2006).

evidence: human trials, mostly short, of different products. in 367 Thai patients with knee osteoarthritis, a turmeric extract was non-inferior to ibuprofen on pain and function over four weeks, with fewer reports of abdominal discomfort (Kuptniratsaikul 2014). in 70 Tasmanian patients with knee osteoarthritis and fluid in the joint on ultrasound, an extract cut knee pain more than placebo over 12 weeks but did not shrink the joint effusion on MRI, in a trial co-funded by a company, Natural Remedies Private Limited (Wang 2020). in colitis, added to standard drugs, curcumin was followed by fewer six-month relapses in 89 people in remission, 2 of 43 against 8 of 39 (Hanai 2006); a Cochrane reanalysis of that single trial put the six-month difference just short of significance and asked for a larger one (Kumar 2012). in 50 people with active colitis not responding to mesalamine, 14 of 26 on curcumin reached remission in four weeks against none of 24 on placebo (Lang 2015). in a review of 32 small trials, 28 of them pooled, C-reactive protein and IL-6 fell (Ferguson 2021).

watch for: liver injury: the US Drug-Induced Liver Injury Network found 10 turmeric cases, all enrolled from 2011 on and 6 since 2017; five people were hospitalized and one died of liver failure, seven carried the immune gene variant HLA-B*35:01, and three of the seven products tested also held black pepper extract (Halegoua-DeMarzio 2023). seven acute hepatitis cases in Tuscany involved turmeric formulations with high bioavailability and high curcumin content (Lombardi 2021). the knee trials ran four to twelve weeks, short for something taken for years.

02Boswelliasmall human trials

the guide

the gum resin of Boswellia serrata, Indian frankincense. its classic mechanism is lab work: boswellic acids, the acetyl-keto form most of all, blocked leukotriene production by 5-lipoxygenase in rat white cells (Safayhi 1992). outside rat cells that story is weaker: the acids failed to block leukotriene formation in human whole blood in the lab, and blood levels of the two key acids after swallowing sit far below the concentrations active in the lab, which makes 5-lipoxygenase inhibition a questionable explanation (Abdel-Tawab 2011).

evidence: small human trials. a 2014 Cochrane review pooled two knee trials of one enriched extract, 85 people in all, and after 90 days knee pain was 17 points lower than on placebo on a 100-point scale (Cameron 2014); both trials came from one author team at the Laila Impex R&D Center (Sengupta 2008; Sengupta 2010). an earlier 30-patient crossover trial from Nagpur also reported less knee pain (Kimmatkar 2003). in the gut, one extract matched mesalazine in 102 people with active Crohn's disease (Gerhardt 2001), while another, tested against placebo in 82 people in remission, did no better at keeping them there and was stopped early (Holtmeier 2011). in 44 people having brain radiotherapy, swelling around the tumor fell by more than three quarters in 60% on boswellia against 26% on placebo (Kirste 2011).

watch for: an extract's name does not say which acids reach the blood: products differ in their boswellic acids, and the acids differ in how well they are absorbed (Abdel-Tawab 2011). the knee trials ran 8 to 13 weeks, and Cochrane found side-effect reporting too uneven to say whether harms rise, though no serious adverse events were reported (Cameron 2014).

03Quercetinsmall human trials

the guide

a flavonol found in onions and tea, sold for inflammation and allergy. how much is absorbed depends on its sugar form: in nine people with ileostomies, 52% of the quercetin glucosides in fried onions was absorbed, against 24% of pure quercetin and 17% of the tea form, rutinoside (Hollman 1995).

evidence: small human trials with mixed results. meta-analyses disagree on blood markers: one found no overall effect on C-reactive protein, IL-6 or TNF-alpha (Ou 2019), another a small C-reactive protein drop across seven trials (Mohammadi-Sartang 2017). in 50 Iranian women with rheumatoid arthritis, eight weeks of quercetin improved morning stiffness, pain and disease-activity scores against placebo (Javadi 2017). in 40 trained cyclists, quercetin did not change the immune responses to three days of heavy exercise, though fewer upper respiratory infections were recorded in the two weeks after, 1 of 20 against 9 of 20 (Nieman 2007). in 30 men with chronic pelvic pain, 67% of those who finished on quercetin improved by at least a quarter, against 20% on placebo (Shoskes 1999).

watch for: drug interactions are real and change direction from drug to drug: a week of quercetin raised blood levels of fexofenadine 55% in 12 healthy volunteers (Kim 2009), while a German group saw trends toward lower exposure to talinolol and oral midazolam (Nguyen 2014; Nguyen 2015). given by vein in a cancer phase 1 trial, its dose-limiting harm was kidney toxicity (Ferry 1996); that was an infusion, not a capsule.

04Bromelainsmall, mixed human trials

the guide

a crude extract of pineapple stem containing several closely related protein-cutting enzymes (Maurer 2001). small amounts reach the blood intact: in 19 healthy men, undegraded bromelain was found in plasma after oral intake (Castell 1997). in the EU, a bromelain-enriched enzyme concentrate, NexoBrid, is a licensed medicine for removing dead tissue from deep burns, and it is applied to the skin, not swallowed (EMA).

evidence: small human trials, mixed. in 47 people with moderate to severe knee osteoarthritis, 12 weeks of bromelain did no better than placebo, with 31 finishing (Brien 2006); in a 40-patient pilot, bromelain did not differ from diclofenac at four weeks and the authors called the comparison inconclusive (Kasemsuk 2016). after wisdom-tooth surgery, two 2019 meta-analyses of six trials each agreed on less pain by day seven but disagreed on swelling (Liu 2019; Mendes 2019). a larger knee trial tested bromelain inside an enzyme mix with trypsin and rutoside, not on its own: in 103 patients the mix was non-inferior to diclofenac over six weeks (Akhtar 2004).

watch for: bromelain is an allergen: a pharmaceutical worker who handled it developed IgE-driven asthma, and five of six workers sensitized to papain also reacted to bromelain (Baur 1979). the enzyme affects clotting in lab work, blocking platelet aggregation in a test tube and reducing thrombus formation in rats (Metzig 1999); in two observational studies of 260 surgical patients on heparin, clotting tests barely moved with bromelain or with diclofenac (Johann 2011).

05KPVanimal and cell only

the guide

a research peptide, Lys-Pro-Val, the last three amino acids of alpha-MSH (Kannengiesser 2008). its proposed route in the gut is a transporter: PepT1 carries KPV into gut-lining and immune cells (Dalmasso 2008), and PepT1 appears in inflamed colon from people with ulcerative colitis or Crohn's disease but not in normal colon (Merlin 2001).

evidence: cells and mice only. in human gut and T-cell lines, nanomolar KPV damped NF-kB and MAP kinase signaling, and KPV in drinking water eased chemically induced colitis in mice (Dalmasso 2008). a Muenster group found faster recovery in two mouse colitis models, partly independent of the MC1 receptor (Kannengiesser 2008). FDA has not identified any human exposure data on products containing KPV by any route (FDA, page current as of 22 April 2026).

watch for: the low-dose mouse results needed a carrier that a vial does not have: packed into nanoparticles inside a colon-targeted gel, KPV matched free KPV's effect at a concentration 12,000 times lower (Laroui 2010). FDA lists KPV among compounding substances that were in its category of significant safety risks until their nominators withdrew them, and says it lacks information on whether KPV would cause harm in people. WADA's 2026 list does not name KPV, but its S0 class covers any pharmacological substance not addressed elsewhere on the list that has no current approval for human therapeutic use.

06BPC-157small human reports, abstract-only trials

the guide

a research peptide: a 15-amino-acid fragment of a protein found in human gastric juice, sold with a reputation for damping inflammation that comes from rat work (Sikiric 1997; FDA briefing, May 2026). FDA states that its molecular targets have not been identified (FDA briefing, May 2026).

evidence: mostly rats, mostly one laboratory: 174 of the 228 PubMed records that name BPC-157 in the title or abstract list Predrag Sikiric of the University of Zagreb as an author (search run 25 October 2026). his group reported less NSAID damage to the gut and less adjuvant arthritis in rats given BPC-157 (Sikiric 1997). in people, the randomized studies exist only as meeting abstracts: an enema study in 32 healthy volunteers and a two-week enema trial in 53 people with ulcerative colitis, where the confidence interval for the difference from placebo crossed zero and FDA found a lack of evidence that BPC-157 works (FDA briefing, May 2026). a 2026 systematic review found three small uncontrolled reports, 30 people in all, and rated the certainty very low (Poolton 2026).

watch for: FDA reports that BPC-157 was not detected in plasma after the enemas and found no human pharmacokinetic data after oral, subcutaneous, nasal or skin use, so the one gut trial says nothing about the dry-fill units sold (FDA briefing, May 2026). FDA found no carcinogenicity study. FDA lists BPC-157 among compounding substances that were in its category of significant safety risks until their nominators withdrew them, and says it lacks the information to know whether BPC-157 would cause harm in people. WADA's 2026 list names BPC-157 under S0, prohibited at all times.

the Anti-Inflammatory Supplements bench keeps four supplements, curcumin, boswellia, quercetin and bromelain, apart from two research peptides. the supplements have randomized human trials of mixed size and quality, BPC-157 has meeting abstracts and small uncontrolled reports, and KPV has no human data at all. no study has tested the four supplements together or paired any of them with a peptide, and the bench gives no amounts and no timing. the Anti-Inflammatory Supplements bench covers 6 compounds: Curcumin, Boswellia, Quercetin, Bromelain, KPV, BPC-157.